FDA – Considerations for including tissue biopsies in clinical trials
FDA has issued a draft guidance to provide recommendations to industry, investigators, institutions, and institutional review boards regarding considerations for tissue biopsies that may be conducted in adults and in children as part of clinical trials that evaluate investigational medical products and/or that are conducted or supported by the Department of Health and Human Services. Comments can be submitted until 10th March 2025.
News reported on the 31st of January 2025 in Catapult’s regulatory round-up, read the entire report here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (20 mai 2025). FDA – Considerations for including tissue biopsies in clinical trials. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/13yf3





